EX-10.1
from 8-K
16 pages
This Contingent Value Rights Agreement, Dated as of [●], 2015 (This “Agreement”), Is Entered Into by and Among Midatech Pharma PLC, a Public Limited Liability Company Organized Under the Laws of England and Wales (“Parent”), DARA Biosciences, Inc., a Delaware Corporation (The “Company”), Shareholder Representative Services LLC, a Colorado Limited Liability Company, Solely in Its Capacity as Representative of the Holders (As Defined Herein) (The “Holder Representative”) and [●], a [●], as Initial Rights Agent (As Defined Herein)
12/34/56
EX-10.1
from DEFA14A
16 pages
This Contingent Value Rights Agreement, Dated as of [●], 2015 (This “Agreement”), Is Entered Into by and Among Midatech Pharma PLC, a Public Limited Liability Company Organized Under the Laws of England and Wales (“Parent”), DARA Biosciences, Inc., a Delaware Corporation (The “Company”), Shareholder Representative Services LLC, a Colorado Limited Liability Company, Solely in Its Capacity as Representative of the Holders (As Defined Herein) (The “Holder Representative”) and [●], a [●], as Initial Rights Agent (As Defined Herein)
12/34/56